Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing
Drug Testing and Analysis · 2026
DOI: 10.1002/dta.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2026. Verfasst von Sergi Coll und 5 weiteren Autor:innen. Beteiligte Einrichtung: Catalonian Antidoping Laboratory, Doping Control Research Group, Hospital del Mar Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Pregnenediones, Substance Abuse Detection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Antidoping Agency, Consell Català de l'Esport (Generalitat de Catalunya), AGAUR (Generalitat de Catalunya).
Abstract (Originalsprache)
Deflazacort (DEF) is a glucocorticoid prohibited in sports competitions when orally administered. This study aimed to assess the urinary and plasma excretion profiles of DEF and its metabolites after a single oral administration to verify the World Anti‐Doping Agency's minimum reporting level (MRL) of 30 ng/mL to detect administration of DEF. DEF was orally administered to eight healthy male participants (30 mg). Urine and plasma samples were collected before and after administration, and DEF and its metabolites were quantified using liquid chromatography–tandem mass spectrometry. Urinary concentrations confirmed that DEF is rapidly metabolized to 21‐desacetyl‐deflazacort (DES), with minimal detection of unchanged DEF. DES and the 6‐hydroxy metabolites, 6βOHDES and 6αOHDES, were present in most urine samples during the first 48 h post‐administration. DES peaked early (0–4 h) and declined below 30 ng/mL after 24 h, while 6βOHDES peaked later (4–8 h) and remained above 30 ng/mL until 36–48 h. 6αOHDES was detected at lower concentrations and cleared rapidly. In plasma, DES and 6βOHDES were detected within 8 h, with DES showing higher peak levels and longer half‐life. DEF itself was not detected in plasma. Pharmacokinetic modeling showed good agreement between urinary and plasma excretion data. Cortisol levels were suppressed post‐dose, indicating systemic GC activity, but recovered by 72 h in most subjects. The findings support the use of DES as the primary urinary marker for DEF detection, confirm the suitability of the MRL of 30 ng/mL and support the recommendation of a 3‐day washout period due to interindividual variability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Catalonian Antidoping Laboratory, Doping Control Research Group, Hospital del Mar Research Institute, Barcelona, Spain.
- Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
- Clinical Research Unit, Hospital del Mar Research Institute, Barcelona, Spain.
- Integrative Pharmacology and Systems Neuroscience Group FINS, Hospital del Mar Research Institute, Barcelona, Spain.
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
ORCID-Profile: Sergi Coll, Claudia Bressan, Núria Monfort, Ana Aldea-Perona, Marcel Lí Carbó, Rosa Ventura
Förderung
- World Antidoping Agency
- Consell Català de l'Esport (Generalitat de Catalunya)
- AGAUR (Generalitat de Catalunya)
- Agència de Gestió d'Ajuts Universitaris i de Recerca
Zitieren
APA
Coll, S., Bressan, C., Monfort, N., Aldea-Perona, A., Carbó, M. L., & Ventura, R. (2026). Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing. Drug Testing and Analysis. https://doi.org/10.1002/dta.70093
Vancouver
Coll S, Bressan C, Monfort N, Aldea-Perona A, Carbó ML, Ventura R. Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing. Drug Testing and Analysis. 2026. doi:10.1002/dta.70093
BibTeX
@article{Coll2026,
author = {Coll, Sergi and Bressan, Claudia and Monfort, Núria and Aldea-Perona, Ana and Carbó, Marcel Lí and Ventura, Rosa},
title = {Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing},
journal = {Drug Testing and Analysis},
year = {2026},
doi = {10.1002/dta.70093}
}
EUVIMED